A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC

Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Dompe, Nicholas, Klijn, Christiaan, Watson, Sara A., Leng, Katherine, Port, Jenna, Cuellar, Trinna, Watanabe, Colin, Haley, Benjamin, Neve, Richard, Evangelista, Marie, Stokoe, David
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005515/
https://ncbi.nlm.nih.gov/pubmed/29912950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0199264
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker